Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Evaluating a Health Care Disparity Among Marine Recruits Treated for Acute Appendicitis.

Prieto JM, Thompson KA, Wessels L, Moore HN, Hannon MP, Ignacio RC.

Mil Med. 2018 Jul 3. doi: 10.1093/milmed/usy146. [Epub ahead of print]

PMID:
29982574
2.

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells.

Ressa A, Bosdriesz E, de Ligt J, Mainardi S, Maddalo G, Prahallad A, Jager M, de la Fonteijne L, Fitzpatrick M, Groten S, Altelaar AFM, Bernards R, Cuppen E, Wessels L, Heck AJR.

Mol Cell Proteomics. 2018 Jul 3. pii: mcp.RA117.000486. doi: 10.1074/mcp.RA117.000486. [Epub ahead of print]

3.

Consensus molecular subtypes classification of colorectal adenomas.

Komor MA, Bosch LJ, Bounova G, Bolijn AS, van-Diemen PD, Rausch C, Hoogstrate Y, Stubbs AP, de Jong M, Jenster G, van Grieken NC, Carvalho B, Wessels LF, Jimenez CR, Fijneman RJ, Meijer GA; NGS-ProToCol Consortium, Dits N, Böttcher R, Hiemstra AC, Ylstra B, Sie D, van den Broek E, van der Meer D, Pepers F, Caldenhoven E, Janssen B, van Workum W, van Lieshout S, Bangma CH, van Leenders G, van de Werken H.

J Pathol. 2018 Jul 3. doi: 10.1002/path.5129. [Epub ahead of print]

PMID:
29968252
4.

Modelling Signalling Networks from Perturbation Data.

Dorel M, Klinger B, Gross T, Sieber A, Prahallad A, Bosdriesz E, Wessels L, Blüthgen N.

Bioinformatics. 2018 Jun 19. doi: 10.1093/bioinformatics/bty473. [Epub ahead of print]

PMID:
29931053
5.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008.

PMID:
29894693
6.

Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer.

Vossen DM, Verhagen CVM, Verheij M, Wessels LFA, Vens C, van den Brekel MWM.

Oral Oncol. 2018 Jun;81:35-44. doi: 10.1016/j.oraloncology.2018.04.006. Epub 2018 Apr 13.

PMID:
29884412
7.

Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines.

Jastrzebski K, Thijssen B, Kluin RJ, de Lint K, Majewski IJ, Beijersbergen RL, Wessels LFA.

Cancer Res. 2018 May 29. pii: canres.2698.2017. doi: 10.1158/0008-5472.CAN-17-2698. [Epub ahead of print]

PMID:
29844118
8.

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, Spinozzi D, de Jong J, van der Poel H, de Boer JP, Wessels LFA, Zwart W, Bergman AM.

Mol Oncol. 2018 May 28. doi: 10.1002/1878-0261.12327. [Epub ahead of print]

9.

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS, Rueda OM, Bosdriesz E, Caldas C, Wessels LFA, Bernards R.

Cell Res. 2018 Jul;28(7):719-729. doi: 10.1038/s41422-018-0044-4. Epub 2018 May 24.

10.

Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma.

Verhagen CVM, Vossen DM, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M, Mout L, Kluin RJC, Nieuwland M, Severson TM, Velds A, Kerkhoven R, O'Connor MJ, van der Heijden M, van Velthuysen ML, Verheij M, Wreesmann VB, Wessels LFA, van den Brekel MWM, Vens C.

Oncotarget. 2018 Apr 6;9(26):18198-18213. doi: 10.18632/oncotarget.24797. eCollection 2018 Apr 6.

11.

Bypass in neurosurgery-indications and techniques.

Wessels L, Hecht N, Vajkoczy P.

Neurosurg Rev. 2018 Mar 13. doi: 10.1007/s10143-018-0966-9. [Epub ahead of print] Review.

PMID:
29536207
12.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

Severson TM, Kim Y, Joosten SEP, Schuurman K, van der Groep P, Moelans CB, Ter Hoeve ND, Manson QF, Martens JW, van Deurzen CHM, Barbe E, Hedenfalk I, Bult P, Smit VTHBM, Linn SC, van Diest PJ, Wessels L, Zwart W.

Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2.

13.

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, Tice DA, Alrifai D, von Karstedt S, Montinaro A, Guppy N, Waller DA, Nakas A, Good R, Holmes A, Walczak H, Fennell DA, Garnett M, Iorio F, Wessels L, McDermott U, Janes SM.

Elife. 2018 Jan 18;7. pii: e30224. doi: 10.7554/eLife.30224.

14.

Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.

Ikink GJ, Boer M, Bakker ERM, Vendel-Zwaagstra A, Klijn C, Ten Hoeve J, Jonkers J, Wessels LF, Hilkens J.

Oncogene. 2018 Mar;37(12):1594-1609. doi: 10.1038/s41388-017-0031-0. Epub 2018 Jan 12.

PMID:
29326437
15.

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, Korving J, van Boxtel R, Duarte AA, Lelieveld D, van Hoeck A, Ernst RF, Blokzijl F, Nijman IJ, Hoogstraat M, van de Ven M, Egan DA, Zinzalla V, Moll J, Boj SF, Voest EE, Wessels L, van Diest PJ, Rottenberg S, Vries RGJ, Cuppen E, Clevers H.

Cell. 2018 Jan 11;172(1-2):373-386.e10. doi: 10.1016/j.cell.2017.11.010. Epub 2017 Dec 7.

PMID:
29224780
16.

Technical accuracy of the integration of an external ultrasonography system into a navigation platform: effects of ultrasonography probe registration and target detection.

Wanis FA, Wessels L, Reinges MHT, Uhl E, Jödicke A.

Acta Neurochir (Wien). 2018 Feb;160(2):305-316. doi: 10.1007/s00701-017-3416-5. Epub 2017 Dec 8.

PMID:
29222590
17.

Bayesian data integration for quantifying the contribution of diverse measurements to parameter estimates.

Thijssen B, Dijkstra TMH, Heskes T, Wessels LFA.

Bioinformatics. 2018 Mar 1;34(5):803-811. doi: 10.1093/bioinformatics/btx666.

PMID:
29069283
18.

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

Stelloo S, Nevedomskaya E, Kim Y, Hoekman L, Bleijerveld OB, Mirza T, Wessels LFA, van Weerden WM, Altelaar AFM, Bergman AM, Zwart W.

Oncogene. 2018 Jan 18;37(3):313-322. doi: 10.1038/onc.2017.330. Epub 2017 Sep 18.

PMID:
28925401
19.

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.

Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, Doshi P, Lips EH, Wessels LFA, de Visser KE.

Oncoimmunology. 2017 Jun 19;6(8):e1334744. doi: 10.1080/2162402X.2017.1334744. eCollection 2017.

20.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

21.

Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-Rodriguez J, McDermott U, Choudhary JS.

Cell Rep. 2017 Aug 29;20(9):2201-2214. doi: 10.1016/j.celrep.2017.08.010.

22.

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L.

Breast Cancer Res. 2017 Aug 25;19(1):99. doi: 10.1186/s13058-017-0861-2.

23.

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM.

Nature. 2017 Sep 7;549(7670):106-110. doi: 10.1038/nature23669. Epub 2017 Aug 16.

PMID:
28813410
24.

Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER+/HER2- Breast Cancer.

van der Velden BHM, Elias SG, Bismeijer T, Loo CE, Viergever MA, Wessels LFA, Gilhuijs KGA.

Clin Cancer Res. 2017 Nov 1;23(21):6505-6515. doi: 10.1158/1078-0432.CCR-17-0176. Epub 2017 Aug 8.

PMID:
28790119
25.

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

Pencheva N, de Gooijer MC, Vis DJ, Wessels LFA, Würdinger T, van Tellingen O, Bernards R.

Cell Rep. 2017 Jul 5;20(1):48-60. doi: 10.1016/j.celrep.2017.06.036.

26.

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, Drenth AP, van der Burg E, Klijn C, Ten Hoeve JJ, Adams DJ, Koudijs MJ, Wesseling J, Nethe M, Wessels LFA, Jonkers J.

Nat Genet. 2017 Aug;49(8):1219-1230. doi: 10.1038/ng.3905. Epub 2017 Jun 26.

PMID:
28650484
27.

Identifying transposon insertions and their effects from RNA-sequencing data.

de Ruiter JR, Kas SM, Schut E, Adams DJ, Koudijs MJ, Wessels LFA, Jonkers J.

Nucleic Acids Res. 2017 Jul 7;45(12):7064-7077. doi: 10.1093/nar/gkx461.

28.

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape.

Vis DJ, Lewin J, Liao RG, Mao M, Andre F, Ward RL, Calvo F, Teh BT, Camargo AA, Knoppers BM, Sawyers CL, Wessels LFA, Lawler M, Siu LL, Voest E; Clinical Working Group of the Global Alliance for Genomics and Health.

Ann Oncol. 2017 May 1;28(5):1145-1151. doi: 10.1093/annonc/mdx037.

29.

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

Gallenne T, Ross KN, Visser NL, Salony, Desmet CJ, Wittner BS, Wessels LFA, Ramaswamy S, Peeper DS.

Oncotarget. 2017 Mar 15;8(13):20572-20587. doi: 10.18632/oncotarget.16244.

30.

Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.

van der Zanden LFM, Vermeulen SH, Oskarsdottir A, Maurits JSF, Diekstra MHM, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LALM, Oosterwijk E.

Urol Oncol. 2017 Aug;35(8):529.e9-529.e16. doi: 10.1016/j.urolonc.2017.03.009. Epub 2017 Apr 3.

31.

Point-of-Care Testing in Neurosurgery.

Beynon C, Wessels L, Unterberg AW.

Semin Thromb Hemost. 2017 Jun;43(4):416-422. doi: 10.1055/s-0037-1599159. Epub 2017 Mar 27. Review.

PMID:
28346963
32.

Discriminative Thresholds in Facial Asymmetry: A Review of the Literature.

Wang TT, Wessels L, Hussain G, Merten S.

Aesthet Surg J. 2017 Apr 1;37(4):375-385. doi: 10.1093/asj/sjw271. Review.

PMID:
28200081
33.

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LF, Zwart W.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1316-E1325. doi: 10.1073/pnas.1615233114. Epub 2017 Feb 6. Erratum in: Proc Natl Acad Sci U S A. 2018 Jan 22;:. Mourits, Marian [corrected to Mourits, Marian J].

35.

Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy.

Knijnenburg TA, Klau GW, Iorio F, Garnett MJ, McDermott U, Shmulevich I, Wessels LF.

Sci Rep. 2016 Nov 23;6:36812. doi: 10.1038/srep36812.

36.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R.

Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. Epub 2016 May 12.

37.

BCM: toolkit for Bayesian analysis of Computational Models using samplers.

Thijssen B, Dijkstra TM, Heskes T, Wessels LF.

BMC Syst Biol. 2016 Oct 21;10(1):100.

38.

Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition.

Koppens MA, Bounova G, Cornelissen-Steijger P, de Vries N, Sansom OJ, Wessels LF, van Lohuizen M.

Oncotarget. 2016 Oct 25;7(43):69816-69828. doi: 10.18632/oncotarget.12002.

39.

TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types.

Aben N, Vis DJ, Michaut M, Wessels LF.

Bioinformatics. 2016 Sep 1;32(17):i413-i420. doi: 10.1093/bioinformatics/btw449.

PMID:
27587657
40.

PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.

Boelens MC, Nethe M, Klarenbeek S, de Ruiter JR, Schut E, Bonzanni N, Zeeman AL, Wientjens E, van der Burg E, Wessels L, van Amerongen R, Jonkers J.

Cell Rep. 2016 Aug 23;16(8):2087-2101. doi: 10.1016/j.celrep.2016.07.059. Epub 2016 Aug 11.

41.

A Landscape of Pharmacogenomic Interactions in Cancer.

Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ.

Cell. 2016 Jul 28;166(3):740-754. doi: 10.1016/j.cell.2016.06.017. Epub 2016 Jul 7.

42.

RUBIC identifies driver genes by detecting recurrent DNA copy number breaks.

van Dyk E, Hoogstraat M, Ten Hoeve J, Reinders MJ, Wessels LF.

Nat Commun. 2016 Jul 11;7:12159. doi: 10.1038/ncomms12159.

43.

Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells.

Koppens MA, Bounova G, Gargiulo G, Tanger E, Janssen H, Cornelissen-Steijger P, Blom M, Song JY, Wessels LF, van Lohuizen M.

Gastroenterology. 2016 Oct;151(4):684-697.e12. doi: 10.1053/j.gastro.2016.06.020. Epub 2016 Jun 21.

PMID:
27342214
44.

OncoScape: Exploring the cancer aberration landscape by genomic data fusion.

Schlicker A, Michaut M, Rahman R, Wessels LF.

Sci Rep. 2016 Jun 20;6:28103. doi: 10.1038/srep28103.

45.

Defining chromosomal translocation risks in cancer.

Hogenbirk MA, Heideman MR, de Rink I, Velds A, Kerkhoven RM, Wessels LF, Jacobs H.

Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3649-56. doi: 10.1073/pnas.1602025113. Epub 2016 Jun 14.

46.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.

Cancer Res. 2016 Jul 1;76(13):3773-84. doi: 10.1158/0008-5472.CAN-14-1813. Epub 2016 May 6. Erratum in: Cancer Res. 2018 May 1;78(9):2446.

47.

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.

de Lint K, Poell JB, Soueidan H, Jastrzebski K, Vidal Rodriguez J, Lieftink C, Wessels LF, Beijersbergen RL.

Mol Cancer Ther. 2016 Jul;15(7):1545-56. doi: 10.1158/1535-7163.MCT-15-0865. Epub 2016 May 11.

48.

Multilevel models improve precision and speed of IC50 estimates.

Vis DJ, Bombardelli L, Lightfoot H, Iorio F, Garnett MJ, Wessels LF.

Pharmacogenomics. 2016 May;17(7):691-700. doi: 10.2217/pgs.16.15. Epub 2016 May 16.

PMID:
27180993
49.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.

Oncotarget. 2016 Jun 7;7(23):33901-18. doi: 10.18632/oncotarget.8983.

50.

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R.

Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059.

Supplemental Content

Loading ...
Support Center